Clinical trials: Schizophrenia / Schizoaffective Disorder
Schizophrenia, Schizoaffective Disorder
Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia
This study in patients with schizophrenia is designed to provide preliminary evidence of the safety, tolerability, and pharmacokinetics as well as the effects on cognitive function of 2 doses of EVP-6124 compared with placebo…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Trial name
- NCT01556763
- Testing
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Antipsychotic therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- FORUM Pharmaceuticals Inc
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
The purpose of this study is to determine if zonisamide SR will prevent weight gain in schizophrenic subjects who take olanzapine (Zyprexa)
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00734435
- Testing
- zonisamide SR plus olanzapine
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Orexigen Therapeutics, Inc
Schizophrenia, Schizoaffective Disorder
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
Digital medicine systems (DMS) have been designed to assist individuals with the management of their daily health, wellness, and medication use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, First Episode Psychosis
- Trial name
- NCT03568500
- Testing
- Digital Medicine System, Aripiprazole, Olanzapine
- Where
- 5 sites in United Kingdom
- Volunteers
- 44 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
PROFILe3: Epidemiologic Survey in Patients With Schizophrenia or Schizoaffective Disorders
The purpose of this study is to evaluate epidemiological characteristics of patients that experience relapse and need an admission in psychiatric acute units across Spain.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00399334
- Testing
- antipsychotic medications
- Volunteers
- 1,607 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorders
Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder
The purpose of this study is to determine whether increasing the amount (dose) of quetiapine IR (immediate release formulation) more rapidly than conventional dose increases, improves the control of symptoms as measured by the…
- Conditions
- Schizophrenia, Schizoaffective Disorders, Psychotic Disorders
- Trial name
- RAPID (NCT00457899)
- Testing
- Quetiapine IR (Immediate Release)
- Where
- 12 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorders
Seroquel STACK Study in Schizophrenic or Schizoaffective Subjects
The purpose of the study is to assess and compare the side effect profile, safety, tolerability and efficacy of schizophrenic or schizoaffective subjects non- or partially- responsive to 800 mg/day of quetiapine treated with…
- Trial name
- NCT00328978
- Testing
- Quetiapine
- Where
- 17 sites in Canada
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia.
- Trial name
- NCT07659938
- Testing
- Frontal gamma coherence neurofeedback
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioSignal Solutions LLC
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Schizophrenia, Schizoaffective Disorder
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or schizoaffective disorder after 6 weeks of…
- Trial name
- NCT02901587
- Testing
- Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day)
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- H. Lundbeck A/S
Bipolar Disorder
A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders
The purpose of this study is to assess the potential pharmacokinetic (absorption, distribution and excretion of the drug by the body) interaction between, and the safety of, topiramate and risperidone administered in combination…
- Trial name
- NCT00986336
- Testing
- topiramate, risperidone
- Volunteers
- 56 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar Disorder
A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders
The purpose of this study is to evaluate the safety and tolerability of oral ziprasidone in children and teens with psychotic disorders
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT00650611
- Testing
- Ziprasidone
- Where
- 17 sites in United States
- Volunteers
- 63 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Tardive Dyskinesia
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00917293
- Testing
- Pyridoxal 5'-Phosphate
- Where
- 4 sites in Canada, India
- Volunteers
- 53 people
- Sponsor
- Medicure
Schizophrenia, Schizoaffective Disorder
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective…
- Trial name
- NCT00558298
- Testing
- risperidone
- Volunteers
- 811 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizoaffective Disorder
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Lyndra Therapeutics, Inc., is developing a long-acting oral (LAO) treatment of risperidone (LYN-005) in a capsule dosage form (LYNX® drug delivery platform).
- Trial name
- Starlyng-2 (NCT06878833)
- Testing
- LYN-005 (risperidone), IR Risperidone
- Sponsor
- Lyndra Inc.
Schizophrenia, Schizoaffective Disorder
Seroquel Long-Term NIS for Schizophrenia Patients
To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder
- Trial name
- SELECT (NCT00523783)
- Where
- 3 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca